{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alcohol+administration%3B+Placebo+administration&page=3",
    "query": {
      "intervention": "Alcohol administration; Placebo administration",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 566,
    "total_pages": 57,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alcohol+administration%3B+Placebo+administration&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Alcohol+administration%3B+Placebo+administration&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T09:28:51.131Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01573052",
      "title": "Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alcohol Withdrawal"
      ],
      "interventions": [
        {
          "name": "Chlordiazepoxide",
          "type": "DRUG"
        },
        {
          "name": "Gabapentin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Salt Lake City Health Care System",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 26,
      "start_date": "2004-03",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2020-08-17",
      "last_synced_at": "2026-10-20T09:28:51.131Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01573052"
    },
    {
      "nct_id": "NCT00106106",
      "title": "Acamprosate to Reduce Symptoms of Alcohol Withdrawal",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol-Related Disorders",
        "Alcohol Dependence",
        "Alcoholism",
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "NMR-spectroscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Oral acamprosate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 56,
      "start_date": "2005-03",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2012-01-12",
      "last_synced_at": "2026-10-20T09:28:51.131Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00106106"
    },
    {
      "nct_id": "NCT00304707",
      "title": "Effectiveness of Bupropion for Smokers Recovering From Alcohol Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Smoking Cessation",
        "Alcohol-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Bupropion",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 143,
      "start_date": "2005-04",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-10-20T09:28:51.131Z",
      "location_count": 1,
      "location_summary": "Bedford, Massachusetts",
      "locations": [
        {
          "city": "Bedford",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00304707"
    },
    {
      "nct_id": "NCT02091206",
      "title": "A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy",
        "Dravet Syndrome"
      ],
      "interventions": [
        {
          "name": "GWP42003-P 5 mg/kg/day Dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo control",
          "type": "DRUG"
        },
        {
          "name": "GWP42003-P 10 mg/kg/day Dose",
          "type": "DRUG"
        },
        {
          "name": "GWP42003-P 20 mg/kg/day Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "10 Years",
        "sex": "ALL",
        "summary": "4 Years to 10 Years"
      },
      "enrollment_count": 34,
      "start_date": "2014-10-22",
      "completion_date": "2015-03-09",
      "has_results": true,
      "last_update_posted_date": "2022-09-28",
      "last_synced_at": "2026-10-20T09:28:51.131Z",
      "location_count": 8,
      "location_summary": "Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02091206"
    },
    {
      "nct_id": "NCT00916721",
      "title": "Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Smoking Cessation"
      ],
      "interventions": [
        {
          "name": "Propranolol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 113,
      "start_date": "2008-04",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2014-09-19",
      "last_synced_at": "2026-10-20T09:28:51.131Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00916721"
    },
    {
      "nct_id": "NCT03099590",
      "title": "Alkontrol-herbal Effects on Alcohol Drinking",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Drinking",
        "Alcohol Use Disorder",
        "Alcohol Abstinence"
      ],
      "interventions": [
        {
          "name": "kudzu extract, puerarin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo control",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Mclean Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 28,
      "start_date": "2018-01-01",
      "completion_date": "2020-07-01",
      "has_results": false,
      "last_update_posted_date": "2020-07-29",
      "last_synced_at": "2026-10-20T09:28:51.131Z",
      "location_count": 1,
      "location_summary": "Belmont, Massachusetts",
      "locations": [
        {
          "city": "Belmont",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03099590"
    },
    {
      "nct_id": "NCT03265808",
      "title": "Allogeneic Human Mesenchymal Stem Cell Infusion vs Placebo in Alcohol Use Disorder and Major Depression.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "allogeneic human mesenchymal stem cells (allo-hMSCs)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ihsan M Salloum, MD, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 31,
      "start_date": "2018-03-18",
      "completion_date": "2025-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-10-20T09:28:51.131Z",
      "location_count": 1,
      "location_summary": "Harlingen, Texas",
      "locations": [
        {
          "city": "Harlingen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03265808"
    },
    {
      "nct_id": "NCT00223691",
      "title": "Treatment of Orthostatic Hypotension in Autonomic Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Autonomic Failure",
        "Orthostatic Hypotension"
      ],
      "interventions": [
        {
          "name": "Atomoxetine",
          "type": "DRUG"
        },
        {
          "name": "Acarbose",
          "type": "DRUG"
        },
        {
          "name": "Pyridostigmine Bromide",
          "type": "DRUG"
        },
        {
          "name": "Yohimbine",
          "type": "DRUG"
        },
        {
          "name": "Midodrine HCl",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "Modafinil",
          "type": "DRUG"
        },
        {
          "name": "Octreotide",
          "type": "DRUG"
        },
        {
          "name": "water intake",
          "type": "OTHER"
        },
        {
          "name": "Diphenhydramine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Ranitidine HCL",
          "type": "DRUG"
        },
        {
          "name": "Tranylcypromine",
          "type": "DRUG"
        },
        {
          "name": "Ergotamine/ Caffeine",
          "type": "DRUG"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "Pseudoephedrine",
          "type": "DRUG"
        },
        {
          "name": "Methylphenidate",
          "type": "DRUG"
        },
        {
          "name": "Indomethacin",
          "type": "DRUG"
        },
        {
          "name": "Ibuprofen",
          "type": "DRUG"
        },
        {
          "name": "Oxymetazoline 0.05% nasal solution",
          "type": "DRUG"
        },
        {
          "name": "Bovril",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Acetazolamide",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine tartrate",
          "type": "DRUG"
        },
        {
          "name": "Carbidopa/levodopa",
          "type": "DRUG"
        },
        {
          "name": "Inflatable abdominal binder",
          "type": "DEVICE"
        },
        {
          "name": "inflatable abdominal binder (sham)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DIETARY_SUPPLEMENT",
        "DEVICE"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 389,
      "start_date": "2002-03",
      "completion_date": "2017-01",
      "has_results": false,
      "last_update_posted_date": "2017-01-18",
      "last_synced_at": "2026-10-20T09:28:51.131Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00223691"
    },
    {
      "nct_id": "NCT01287585",
      "title": "Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Best Supportive Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Polaris Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 636,
      "start_date": "2011-07",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2019-09-06",
      "last_synced_at": "2026-10-20T09:28:51.131Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Coronado, California • La Jolla, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01287585"
    },
    {
      "nct_id": "NCT00951743",
      "title": "Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Adaptavir (monomeric DAPTA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rapid Laboratories Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2009-07",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2009-08-11",
      "last_synced_at": "2026-10-20T09:28:51.131Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00951743"
    }
  ]
}